{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:12:22Z","timestamp":1790734342905,"version":"4.1.0"},"reference-count":129,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T00:00:00Z","timestamp":1639008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Science and Higher education of Russian Federation","award":["075-15-2020-926"],"award-info":[{"award-number":["075-15-2020-926"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bioengineering"],"abstract":"<jats:p>Precise delivery of therapeutics to the target structures is essential for treatment efficiency and safety. Drug administration via conventional routes requires overcoming multiple transport barriers to achieve and maintain the local drug concentration and commonly results in unwanted off-target effects. Patients\u2019 compliance with the treatment schedule remains another challenge. Implantable drug delivery systems (IDDSs) provide a way to solve these problems. IDDSs are bioengineering devices surgically placed inside the patient\u2019s tissues to avoid first-pass metabolism and reduce the systemic toxicity of the drug by eluting the therapeutic payload in the vicinity of the target tissues. IDDSs present an impressive example of successful translation of the research and engineering findings to the patient\u2019s bedside. It is envisaged that the IDDS technologies will grow exponentially in the coming years. However, to pave the way for this progress, it is essential to learn lessons from the past and present of IDDSs clinical applications. The efficiency and safety of the drug-eluting implants depend on the interactions between the device and the hosting tissues. In this review, we address this need and analyze the clinical landscape of the FDA-approved IDDSs applications in the context of the foreign body reaction, a key aspect of implant\u2013tissue integration.<\/jats:p>","DOI":"10.3390\/bioengineering8120205","type":"journal-article","created":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T21:52:32Z","timestamp":1639086752000},"page":"205","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Implantable Drug Delivery Systems and Foreign Body Reaction: Traversing the Current Clinical Landscape"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4137-8993","authenticated-orcid":false,"given":"Alexey","family":"Fayzullin","sequence":"first","affiliation":[{"name":"Department of Experimental Morphology and Biobanking, Institute for Regenerative Medicine, Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia"},{"name":"World-Class Research Center \u201cDigital Biodesign and Personalized Healthcare\u201d, Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia"},{"name":"Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW 2109, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alesia","family":"Bakulina","sequence":"additional","affiliation":[{"name":"Department of Experimental Morphology and Biobanking, Institute for Regenerative Medicine, Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Mikaelyan","sequence":"additional","affiliation":[{"name":"Department of Experimental Morphology and Biobanking, Institute for Regenerative Medicine, Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia"},{"name":"World-Class Research Center \u201cDigital Biodesign and Personalized Healthcare\u201d, Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anatoly","family":"Shekhter","sequence":"additional","affiliation":[{"name":"Department of Experimental Morphology and Biobanking, Institute for Regenerative Medicine, Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8866-9838","authenticated-orcid":false,"given":"Anna","family":"Guller","sequence":"additional","affiliation":[{"name":"Department of Experimental Morphology and Biobanking, Institute for Regenerative Medicine, Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia"},{"name":"World-Class Research Center \u201cDigital Biodesign and Personalized Healthcare\u201d, Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia"},{"name":"Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW 2109, Australia"},{"name":"Biomolecular Discovery Research Centre, Macquarie University, Sydney, NSW 2109, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-198409010-00001","article-title":"First-pass elimination. Basic concepts and clinical consequences","volume":"9","author":"Pond","year":"1984","journal-title":"Clin. Pharmacokinet."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Massot Mesquida, M., de la Fuente, J.A., Andres Lorca, A.M., Arteaga Pillasagua, I., Balboa Blanco, E., Gracia Vidal, S., Pablo Reyes, S., Gomez Iparraguirre, P., Seda Gombau, G., and Toran-Monserrat, P. (2021). Primary Care Records of Chronic-Disease Patient Adherence to Treatment. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18073710"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1046\/j.1365-2710.2001.00363.x","article-title":"Patient adherence to treatment: Three decades of research. A comprehensive review","volume":"26","author":"Vermeire","year":"2001","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-59745-210-6_1","article-title":"Drug delivery systems\u2014An overview","volume":"437","author":"Jain","year":"2008","journal-title":"Methods Mol. Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ijpharm.2017.11.038","article-title":"Generic drug device combination products: Regulatory and scientific considerations","volume":"544","author":"Choi","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/10837450.2018.1509348","article-title":"The road to market implantable drug delivery systems: A review on US FDA\u2019s regulatory framework and quality control requirements","volume":"23","author":"Capasso","year":"2018","journal-title":"Pharm. Dev. Technol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10544-019-0389-6","article-title":"Advanced implantable drug delivery technologies: Transforming the clinical landscape of therapeutics for chronic diseases","volume":"21","author":"Ballerini","year":"2019","journal-title":"Biomed. Microdevices"},{"key":"ref_8","unstructured":"Ratner, B.D., Hoffman, A.S., Schoen, F.J., and Lemons, J.E. (2013). Implants and Inserts. Biomaterials Science, Academic Press."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2014.02.006","article-title":"Evolution of implantable and insertable drug delivery systems","volume":"181","author":"Kleiner","year":"2014","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1109\/TNSRE.2012.2189020","article-title":"An implantable closedloop asynchronous drug delivery system for the treatment of refractory epilepsy","volume":"20","author":"Salam","year":"2012","journal-title":"IEEE Trans. Neural Syst. Rehabil. Eng."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1089\/dia.2017.0142","article-title":"A Prospective Multicenter Evaluation of the Accuracy of a Novel Implanted Continuous Glucose Sensor: PRECISE II","volume":"20","author":"Christiansen","year":"2018","journal-title":"Diabetes Technol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.3109\/03639049109026629","article-title":"Implantable Controlled Release Drug Delivery Systems\u2014A Review","volume":"17","author":"Danckwerts","year":"1991","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"6157","DOI":"10.1039\/C4TB00548A","article-title":"Drug-releasing implants: Current progress, challenges and perspectives","volume":"2","author":"Santos","year":"2014","journal-title":"J. Mater. Chem. B"},{"key":"ref_14","unstructured":"Grumezescu, A.M. (2018). Implantable drug delivery systems. Nanostructures for the Engineering of Cells, Tissues and Organs, William Andrew Publishing."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejpb.2020.12.005","article-title":"Evolution of drug-eluting biomedical implants for sustained drug delivery","volume":"159","author":"Quarterman","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-4804(64)80040-8","article-title":"The use of silicone rubber as a carrier for prolonged drug therapy","volume":"4","author":"Folkman","year":"1964","journal-title":"J. Surg. Res."},{"key":"ref_17","unstructured":"FDA (2021, October 28). IDE Definitions and Acronyms, Available online: https:\/\/www.fda.gov\/medical-devices\/investigational-device-exemption-ide\/ide-definitions-and-acronyms."},{"key":"ref_18","unstructured":"Seyfoddin, A., Dezfooli, S.M., and Greene, C.A. (2020). Implantable drug delivery systems. Engineering Drug Delivery Systems, Woodhead Publishing."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Stewart, S.A., Dominguez-Robles, J., Donnelly, R.F., and Larraneta, E. (2018). Implantable Polymeric Drug Delivery Devices: Classification, Manufacture, Materials, and Clinical Applications. Polymers, 10.","DOI":"10.3390\/polym10121379"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1080\/10837450.2019.1682607","article-title":"Pharmaceutical implants: Classification, limitations and therapeutic applications","volume":"25","author":"Mohtashami","year":"2020","journal-title":"Pharm. Dev. Technol."},{"key":"ref_21","unstructured":"FDA Center for Devices, Radiological Health Center for Biologics Evaluation and Research, and U.S. Department of Health and Human Services Food and Drug Administration (2021, October 26). Biological Evaluation of Medical Devices\u2014Part 1: Evaluation and Testing within a Risk Management Process: Guidance for Industry and Food and Drug Administration Staff, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/use-international-standard-iso-10993-1-biological-evaluation-medical-devices-part-1-evaluation-and."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/jbm.820080503","article-title":"The foreign body reaction: A chronic inflammatory response","volume":"8","author":"Coleman","year":"1974","journal-title":"J. Biomed. Mater. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.smim.2007.11.004","article-title":"Foreign body reaction to biomaterials","volume":"20","author":"Anderson","year":"2008","journal-title":"Semin. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1021\/acsbiomaterials.8b00252","article-title":"The Foreign Body Response Demystified","volume":"5","author":"Chandorkar","year":"2019","journal-title":"ACS Biomater. Sci. Eng."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1002\/adfm.201500875","article-title":"Protein Corona Influences Cell-Biomaterial Interactions in Nanostructured Tissue Engineering Scaffolds","volume":"25","author":"Serpooshan","year":"2015","journal-title":"Adv. Funct. Mater."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"876","DOI":"10.2144\/02324rr05","article-title":"Quantification of fibronectin adsorption to silicone-rubber cell culture substrates","volume":"32","author":"Cunningham","year":"2002","journal-title":"Biotechniques"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/ten.2005.11.1","article-title":"Mediation of biomaterial-cell interactions by adsorbed proteins: A review","volume":"11","author":"Wilson","year":"2005","journal-title":"Tissue Eng."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Chang, H.I., and Wang, Y. (2011). Cell Responses to Surface and Architecture of Tissue Engineering Scaffolds. Regen. Med. Tissue Eng.\u2014Cells Biomater., 569\u2013588.","DOI":"10.5772\/21983"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.imbio.2016.06.010","article-title":"The impact of surface chemistry modification on macrophage polarisation","volume":"221","author":"Rostam","year":"2016","journal-title":"Immunobiology"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Matriano, J. (2021). CHAPTER 7. Addressing Immunogenicity for Implantable Drug-delivery Devices and Long-acting Injectables, Including Pharmacokinetic and Pharmacodynamic Correlations. Implantable Technologies, The Royal Society of Chemistry. Drug Development and Pharmaceutical Science.","DOI":"10.1039\/9781839164958-00131"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1743-6109.2011.02570.x","article-title":"A multi-institutional observational study of testosterone levels after testosterone pellet (Testopel((R))) insertion","volume":"9","author":"McCullough","year":"2012","journal-title":"J. Sex. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11930-014-0033-7","article-title":"A Review of Testosterone Pellets in the Treatment of Hypogonadism","volume":"6","author":"McCullough","year":"2014","journal-title":"Curr. Sex. Health Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1136\/jfprhc-2013-100633","article-title":"Adverse reaction to Nexplanon(R)","volume":"39","author":"Chaudhry","year":"2013","journal-title":"J. Fam. Plan. Reprod. Health Care"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1525-1403.1998.tb00007.x","article-title":"Neurologic sequelae of intraspinal drug delivery systems: Results of a survey of american implanters of implantable drug delivery systems","volume":"1","author":"Schuchard","year":"1998","journal-title":"Neuromodulation"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1211\/jpp.58.3.0002","article-title":"In-vitro and in-vivo characterization of a buprenorphine delivery system","volume":"58","author":"Kleppner","year":"2006","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1055\/s-0030-1248135","article-title":"Contraceptive implants","volume":"28","author":"Burke","year":"2010","journal-title":"Semin. Reprod. Med"},{"key":"ref_37","first-page":"e2132","article-title":"Complications of Subcutaneous Contraception: A Review","volume":"10","author":"Ramdhan","year":"2018","journal-title":"Cureus"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/0029-7844(94)00457-O","article-title":"Serious adverse events in Norplant users reported to the Food and Drug Administration\u2019s MedWatch Spontaneous Reporting System","volume":"85","author":"Wysowski","year":"1995","journal-title":"Obstet. Gynecol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1783\/147118907780254141","article-title":"Fat atrophy at the site of a subdermal contraceptive implant","volume":"33","author":"Moss","year":"2007","journal-title":"J. Fam. Plan. Reprod. Health Care"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.contraception.2004.11.007","article-title":"Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel","volume":"71","author":"Funk","year":"2005","journal-title":"Contraception"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1783\/147118907781004877","article-title":"Expulsion of Implanon","volume":"33","author":"Gwinnell","year":"2007","journal-title":"J. Fam. Plan. Reprod. Health Care"},{"key":"ref_42","first-page":"1","article-title":"A foreign body reaction to a contraceptive implant","volume":"1","author":"Patel","year":"2014","journal-title":"J. Womens Health Gynecol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e8627","DOI":"10.1097\/MD.0000000000008627","article-title":"Removal of a subdermal contraceptive implant (Implanon NXT) that migrated to the axilla by C-arm guidance: A case report and review of the literature","volume":"96","author":"Park","year":"2017","journal-title":"Medicine"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1136\/jfprhc-2013-100639","article-title":"Comment on \u2018Adverse reaction to Nexplanon\u00ae\u2019","volume":"39","author":"Mansour","year":"2013","journal-title":"J. Fam. Plan. Reprod. Health Care"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.contraception.2014.08.014","article-title":"Delayed-type hypersensitivity reaction against Nexplanon(R)","volume":"91","author":"Serati","year":"2015","journal-title":"Contraception"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S0090-4295(01)01192-X","article-title":"Patient-reported experience with the Viadur 12-month leuprolide implant for prostate cancer","volume":"58","author":"Fowler","year":"2001","journal-title":"Urology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1208\/s12248-010-9199-8","article-title":"Critical variables associated with nonbiodegradable osmotically controlled implants","volume":"12","author":"Wright","year":"2010","journal-title":"AAPS J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.eursup.2010.08.004","article-title":"Introducing Vantas: The First Once-Yearly Luteinising Hormone-Releasing Hormone Agonist","volume":"9","author":"Shore","year":"2010","journal-title":"Eur. Urol. Suppl."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jpeds.2013.05.033","article-title":"A single histrelin implant is effective for 2 years for treatment of central precocious puberty","volume":"163","author":"Lewis","year":"2013","journal-title":"J. Pediatr."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1089\/trgh.2020.0055","article-title":"Histrelin Implants for Suppression of Puberty in Youth with Gender Dysphoria: A Comparison of 50 mcg\/Day (Vantas) and 65 mcg\/Day (SupprelinLA)","volume":"6","author":"Streeter","year":"2021","journal-title":"Transgend. Health"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.clinthera.2010.09.009","article-title":"Sterile abscess formation in response to two separate branded long-acting gonadotropin-releasing hormone agonists","volume":"32","author":"Miller","year":"2010","journal-title":"Clin. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/2045125316681984","article-title":"Probuphine(R) (buprenorphine implant): A promising candidate in opioid dependence","volume":"7","author":"Barnwal","year":"2017","journal-title":"Ther. Adv. Psychopharm."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/ADM.0000000000000447","article-title":"Buprenorphine Implant Removal 7 Years Postinsertion: A Case Report","volume":"13","author":"Frost","year":"2019","journal-title":"J. Addict. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1749-6632.1988.tb31812.x","article-title":"Shiley INFUSAID Pump technology","volume":"531","author":"Johnston","year":"1988","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/1097-0142(19860201)57:3<465::AID-CNCR2820570311>3.0.CO;2-S","article-title":"Toxicities and complications of implanted pump hepatic arterial and intravenous floxuridine infusion","volume":"57","author":"Hohn","year":"1986","journal-title":"Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/1097-0142(19860401)57:7<1281::AID-CNCR2820570704>3.0.CO;2-B","article-title":"Fibrosis of Extrahepatic Biliary System after Continuous Hepatic-Artery Infusion of Floxuridine through an Implantable Pump (Infusaid Pump)","volume":"57","author":"Haq","year":"1986","journal-title":"Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(94)91462-1","article-title":"French multicentre experience of implantable insulin pumps. The EVADIAC Study Group. Evaluation of Active Implants in Diabetes Society","volume":"343","author":"Broussolle","year":"1994","journal-title":"Lancet"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3109\/02688699209002912","article-title":"Complications of intrathecal baclofen delivery","volume":"6","author":"Teddy","year":"1992","journal-title":"Br. J. Neurosurg."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/ner.12934","article-title":"Accuracy and Precision of the SynchroMed II Pump","volume":"22","author":"Farid","year":"2019","journal-title":"Neuromodulation"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.chest.2015.11.005","article-title":"Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System: Results of the DelIVery for PAH Trial","volume":"150","author":"Bourge","year":"2016","journal-title":"Chest"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/ner.12010","article-title":"Rate of Complications Among the Recipients of Intrathecal Baclofen Pump in J apan: A Multicenter Study","volume":"16","author":"Taira","year":"2013","journal-title":"Neuromodul. Technol. Neural Interface"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1227\/00006123-199111000-00025","article-title":"Spinal cord compression complicating subarachnoid infusion of morphine: Case report and laboratory experience","volume":"29","author":"North","year":"1991","journal-title":"Neurosurgery"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1213\/01.ANE.0000120086.35289.9D","article-title":"Safety of continuous intrathecal midazolam infusion in the sheep model","volume":"98","author":"Johansen","year":"2004","journal-title":"Anesth. Analg."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1526-4637.2011.01308.x","article-title":"An in vivo canine study to assess granulomatous responses in the MedStream Programmable Infusion System (TM) and the SynchroMed II Infusion System(R)","volume":"13","author":"Michael","year":"2012","journal-title":"Pain Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.apmr.2013.12.019","article-title":"Occurrence of adverse events in long-term intrathecal baclofen infusion: A 1-year follow-up study of 158 adults","volume":"95","author":"Borrini","year":"2014","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"291","DOI":"10.36076\/ppj.2005\/8\/291","article-title":"The diagnosis of intrathecal infusion pump system failure","volume":"8","author":"Jones","year":"2005","journal-title":"Pain Physician"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1526-4637.2011.01090.x","article-title":"Ultrasound-guided intrathecal pump access and prevention of the pocket fill","volume":"12","author":"Gofeld","year":"2011","journal-title":"Pain Med."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Jones, R. (2011). Spinal Cord Stimulation and Implanted Intrathecal Drug Infusion. Pain Procedures in Clinical Practice, Elsevier.","DOI":"10.1016\/B978-1-4160-3779-8.10041-7"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s13244-017-0568-z","article-title":"Plain radiography in patients treated with intrathecal drug delivery using an implantable pump device","volume":"8","author":"Delhaas","year":"2017","journal-title":"Insights Imaging"},{"key":"ref_70","unstructured":"(2021, December 03). Intera 3000. Available online: https:\/\/interaoncology.com\/intera-3000."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"895013","DOI":"10.1155\/2013\/895013","article-title":"Critical assessment of implantable drug delivery devices in glaucoma management","volume":"2013","author":"Manickavasagam","year":"2013","journal-title":"J. Drug Deliv."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0169-409X(01)00193-4","article-title":"Transscleral drug delivery for posterior segment disease","volume":"52","author":"Geroski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"113957","DOI":"10.1016\/j.addr.2021.113957","article-title":"Polymeric long-acting drug delivery systems (LADDS) for treatment of chronic diseases: Inserts, patches, wafers, and implants","volume":"177","author":"Abdelkader","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40123-015-0035-1","article-title":"A Novel Technique for Repositioning of a Migrated ILUVIEN (R) (Fluocinolone Acetonide) Implant into the Anterior Chamber","volume":"4","author":"Saad","year":"2015","journal-title":"Ophthalmol. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: A multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ajo.2006.05.045","article-title":"Cannulation of the suprachoroidal space: A novel drug delivery methodology to the posterior segment","volume":"142","author":"Olsen","year":"2006","journal-title":"Am. J. Ophthalmol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.addr.2012.02.005","article-title":"Reservoir-based drug delivery systems utilizing microtechnology","volume":"64","author":"Stevenson","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_78","first-page":"320","article-title":"A summary of recent advances in ocular inserts and implants","volume":"9","author":"Jervis","year":"2017","journal-title":"J. Bioequiv. Bioavailab."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1056\/NEJM199707103370203","article-title":"Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group","volume":"337","author":"Musch","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0002-9394(98)00443-7","article-title":"Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis","volume":"127","author":"Lim","year":"1999","journal-title":"Am. J. Ophthalmol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0939-6411(03)00138-3","article-title":"Cyclosporine A delivery to the eye: A pharmaceutical challenge","volume":"56","author":"Lallemand","year":"2003","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.ajo.2012.06.004","article-title":"Evaluation of fluocinolone acetonide sustained release implant (Retisert) dissociation during implant removal and exchange surgery","volume":"154","author":"Nicholson","year":"2012","journal-title":"Am. J. Ophthalmol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.ophtha.2006.02.021","article-title":"Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: Thirty-four-week results of a multicenter randomized clinical study","volume":"113","author":"Jaffe","year":"2006","journal-title":"Ophthalmology"},{"key":"ref_84","unstructured":"Berger, B.B. (Retinal Physician, 2012). Fluocinolone Implant for Idiopathic Non-Infectious Posterior Uveitis, Retinal Physician, pp. 2\u20136."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/eye.2009.54","article-title":"Cytomegalovirus endotheliitis following fluocinolone acetonide (Retisert) implant","volume":"24","author":"Sims","year":"2010","journal-title":"Eye"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3109\/09273948.2011.580075","article-title":"Cytomegalovirus endotheliitis after fluocinolone acetonide (Retisert) implant in a patient with Behcet uveitis","volume":"19","author":"Park","year":"2011","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1001\/archopht.126.9.1191","article-title":"Treatment of posterior uveitis with a fluocinolone acetonide implant: Three-year clinical trial results","volume":"126","author":"Callanan","year":"2008","journal-title":"Arch. Ophthalmol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/IIO.0000000000000198","article-title":"Sustained Release Corticosteroid Therapy for Noninfectious Uveitis","volume":"57","author":"Borkar","year":"2017","journal-title":"Int. Ophthalmol. Clin."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/IIO.0000000000000132","article-title":"Intravitreal Steroid Implants in the Management of Retinal Disease and Uveitis","volume":"56","author":"Logan","year":"2016","journal-title":"Int. Ophthalmol. Clin."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jconrel.2014.09.030","article-title":"Implants for drug delivery to the posterior segment of the eye: A focus on stimuli-responsive and tunable release systems","volume":"196","author":"Yasin","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/0300060518816884","article-title":"Intravitreal fluocinolone acetonide implant (ILUVIEN\u00ae) for diabetic macular oedema: A literature review","volume":"47","author":"Massa","year":"2019","journal-title":"J. Int. Med Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/ICB.0000000000000284","article-title":"Observation: Fluocinolone acetonide (ILUVIEN) implant migration into the anterior chamber","volume":"11","author":"Papastavrou","year":"2017","journal-title":"Retin. Cases brief Rep."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"621","DOI":"10.4155\/tde-2019-0051","article-title":"Preliminary evaluation of YUTIQ (fluocinolone acetonide intravitreal implant 0.18 mg) in posterior uveitis","volume":"10","author":"Testi","year":"2019","journal-title":"Ther. Deliv."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.ajo.2008.12.033","article-title":"Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome","volume":"147","author":"Williams","year":"2009","journal-title":"Am. J. Ophthalmol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1167\/iovs.10-5285","article-title":"Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant","volume":"52","author":"Attar","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1080\/09273948.2016.1184284","article-title":"Common and Rare Ocular Side-effects of the Dexamethasone Implant","volume":"25","author":"Jusufbegovic","year":"2017","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1097\/IAE.0000000000001369","article-title":"Safety of intravitreal dexamethasone implant (ozurdex): The SAFODEX study. Incidence and Risk Factors of Ocular Hypertension","volume":"37","author":"Malcles","year":"2017","journal-title":"Retina"},{"key":"ref_98","first-page":"4332","article-title":"I-VationTM TA: 24-month clinical results of the phase I safety and preliminary efficacy study","volume":"50","author":"Dugel","year":"2009","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3928\/23258160-20140501-02","article-title":"Fibrotic encapsulation of a dexamethasone intravitreal implant following vitrectomy and silicone oil for rhegmatogenous retinal detachment","volume":"45","author":"Bakri","year":"2014","journal-title":"Ophthalmic. Surg. Lasers Imaging Retin."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/bjophthalmol-2014-304866","article-title":"Desegmentation of Ozurdex implant in vitreous cavity: Report of two cases","volume":"98","author":"Agrawal","year":"2014","journal-title":"Br. J. Ophthalmol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/ICB.0b013e3182258b08","article-title":"Migration of Ozurdex implant into the anterior chamber","volume":"6","author":"Eadie","year":"2012","journal-title":"Retin. Cases Brief Rep."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s00417-011-1802-x","article-title":"Anterior chamber migration of dexametasone intravitreal implant (Ozurdex(R))","volume":"250","year":"2012","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.2147\/OPTH.S330255","article-title":"Dexamethasone Sustained-Release Intracanalicular Insert for Control of Postoperative Inflammation After Pars Plana Vitrectomy","volume":"15","author":"Suner","year":"2021","journal-title":"Clin. Ophthalmol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1000572","DOI":"10.4172\/2155-9570.1000572","article-title":"Efficacy and Safety of Sustained Release Dexamethasone for the Treatment of Ocular Pain and Inflammation after Cataract Surgery: Results from Two Phase 3 Studies","volume":"7","author":"Walters","year":"2016","journal-title":"J. Clin. Exp. Ophthalmol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"780634","DOI":"10.1155\/2013\/780634","article-title":"Drug delivery implants in the treatment of vitreous inflammation","volume":"2013","author":"Wang","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Holekamp, N.M., Campochiaro, P.A., Chang, M.A., Miller, D., Pieramici, D., Adamis, A.P., Brittain, C., Evans, E., Kaufman, D., and Maass, K.F. (2021). Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology.","DOI":"10.1016\/j.ophtha.2021.09.016"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.biopha.2018.08.138","article-title":"A review on recent drug delivery systems for posterior segment of eye","volume":"107","author":"Nayak","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.drudis.2010.12.004","article-title":"Drug delivery to the posterior segment of the eye","volume":"16","author":"Thrimawithana","year":"2011","journal-title":"Drug Discov. Today"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ophtha.2017.12.029","article-title":"Dexamethasone Intracameral Drug-Delivery Suspension for Inflammation Associated with Cataract Surgery: A Randomized, Placebo-Controlled, Phase III Trial","volume":"125","author":"Donnenfeld","year":"2018","journal-title":"Ophthalmology"},{"key":"ref_110","first-page":"5627","article-title":"VerisomeTM, a Novel injectable, Sustained Release, Biodegradable, Intraocular Drug Delivery System and Triamcinolone Acetonide","volume":"49","author":"Hu","year":"2008","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_111","first-page":"317","article-title":"Sustained release intraocular drug delivery devices for treatment of uveitis","volume":"6","author":"Haghjou","year":"2011","journal-title":"J. Ophthalmic. Vis. Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.1073\/pnas.1018987108","article-title":"Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration","volume":"108","author":"Zhang","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.biomaterials.2013.09.032","article-title":"In vivo performance of a drug-eluting contact lens to treat glaucoma for a month","volume":"35","author":"Ciolino","year":"2014","journal-title":"Biomaterials"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Fisher, J.P., and Adamson, D.C. (2021). Current FDA-Approved Therapies for High-Grade Malignant Gliomas. Biomedicines, 9.","DOI":"10.3390\/biomedicines9030324"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11060-020-03410-1","article-title":"Implantation of carmustine wafers (Gliadel((R))) for high-grade glioma treatment. A 9-year nationwide retrospective study","volume":"147","author":"Champeaux","year":"2020","journal-title":"J. Neurooncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1245\/s10434-008-0048-2","article-title":"Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: A 10-year institutional experience","volume":"15","author":"Attenello","year":"2008","journal-title":"Ann. Surg. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jconrel.2011.11.031","article-title":"Local drug delivery strategies for cancer treatment: Gels, nanoparticles, polymeric films, rods, and wafers","volume":"159","author":"Wolinsky","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1007\/s00701-011-1087-1","article-title":"Gliadel wafers acting as a lattice for bacterial growth: A case illustration","volume":"153","author":"Muntasser","year":"2011","journal-title":"Acta Neurochir."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s11060-017-2733-0","article-title":"Tumor microenvironment after biodegradable BCNU wafer implantation: Special consideration of immune system","volume":"137","author":"Shibahara","year":"2018","journal-title":"J. Neurooncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jocn.2021.01.037","article-title":"Long-term follow-up after BCNU wafer implantation in patients with newly diagnosed glioblastoma","volume":"86","author":"Shibahara","year":"2021","journal-title":"J. Clin. Neurosci."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"848","DOI":"10.2176\/nmc.cr.2015-0186","article-title":"Chronic Phase Intracranial Hemorrhage Caused by Ruptured Pseudoaneurysm Induced by Carmustine Wafer Implantation for Insulo-opercular Anaplastic Astrocytoma: A Case Report","volume":"55","author":"Sato","year":"2015","journal-title":"Neurol. Med. Chir."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jconrel.2019.11.021","article-title":"Functional polymeric nerve guidance conduits and drug delivery strategies for peripheral nerve repair and regeneration","volume":"317","author":"Manoukian","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3389\/fphar.2017.00245","article-title":"Biomaterials for Local, Controlled Drug Delivery to the Injured Spinal Cord","volume":"8","author":"Ziemba","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nrcardio.2010.14","article-title":"New drug-eluting stent concepts","volume":"7","author":"Wessely","year":"2010","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e007023","DOI":"10.1161\/CIRCINTERVENTIONS.118.007023","article-title":"Restenosis of Drug-Eluting Stents: A New Classification System Based on Disease Mechanism to Guide Treatment and State-of-the-Art Review","volume":"12","author":"Shlofmitz","year":"2019","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"610364","DOI":"10.3389\/fcvm.2020.610364","article-title":"Recent Development in Therapeutic Cardiac Patches","volume":"7","author":"Mei","year":"2020","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41569-019-0234-x","article-title":"Drug-eluting coronary stents: Insights from preclinical and pathology studies","volume":"17","author":"Torii","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"364143","DOI":"10.1155\/2014\/364143","article-title":"Five-month observation of persistent diabetic macular edema after intravitreal injection of Ozurdex implant","volume":"2014","author":"Zalewski","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Fayzullin, A., Churbanov, S., Ignatieva, N., Zakharkina, O., Tokarev, M., Mudryak, D., Khristidis, Y., Balyasin, M., Kurkov, A., and Golubeva, E.N. (2021). Local Delivery of Pirfenidone by PLA Implants Modifies Foreign Body Reaction and Prevents Fibrosis. Biomedicines, 9.","DOI":"10.3390\/biomedicines9080853"}],"container-title":["Bioengineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2306-5354\/8\/12\/205\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:44:19Z","timestamp":1760168659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2306-5354\/8\/12\/205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,9]]},"references-count":129,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["bioengineering8120205"],"URL":"https:\/\/doi.org\/10.3390\/bioengineering8120205","relation":{},"ISSN":["2306-5354"],"issn-type":[{"value":"2306-5354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,9]]}}}